{"id":92,"date":"2015-09-25T18:30:21","date_gmt":"2015-09-25T17:30:21","guid":{"rendered":"https:\/\/blogs.ncl.ac.uk\/katarzynapirog\/?p=92"},"modified":"2016-01-20T23:41:56","modified_gmt":"2016-01-20T23:41:56","slug":"new-therapeutic-targets-in-rare-genetic-skeletal-diseases","status":"publish","type":"post","link":"https:\/\/blogs.ncl.ac.uk\/piroglab\/2015\/09\/25\/new-therapeutic-targets-in-rare-genetic-skeletal-diseases\/","title":{"rendered":"New therapeutic targets in rare genetic skeletal diseases &#8211; an Expert Opinion review"},"content":{"rendered":"<header class=\"entry-header\">\n<div class=\"comments-link\"><\/div>\n<\/header>\n<div class=\"entry-content\">\n<p><a href=\"https:\/\/mikebriggs1910.files.wordpress.com\/2015\/09\/new-targets.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-2146\" src=\"https:\/\/mikebriggs1910.files.wordpress.com\/2015\/09\/new-targets.jpg?w=625&amp;h=273\" alt=\"New Targets\" width=\"625\" height=\"273\" \/><\/a><\/p>\n<p><span style=\"color: #3366ff\"><strong>Abstract<\/strong><\/span><\/p>\n<div class=\"paragraph\" style=\"text-align: justify\"><b><i>Introduction:<\/i><\/b> Genetic skeletal diseases (GSDs) are a diverse and complex group of rare genetic conditions that affect the development and homeostasis of the skeleton. Although individually rare, as a group of related diseases, GSDs have an overall prevalence of at least 1 per 4,000 children. There are currently very few specific therapeutic interventions to prevent, halt or modify skeletal disease progression and therefore the generation of new and effective treatments requires novel and innovative research that can identify tractable therapeutic targets and biomarkers of these diseases.<\/div>\n<div class=\"paragraph\" style=\"text-align: justify\"><b><i>Areas covered:<\/i><\/b> Remarkable progress has been made in identifying the genetic basis of the majority of GSDs and in developing relevant model systems that have delivered new knowledge on disease mechanisms and are now starting to identify novel therapeutic targets. This review will provide an overview of disease mechanisms that are shared amongst groups of different GSDs and describe potential therapeutic approaches that are under investigation.<\/div>\n<div class=\"paragraph\" style=\"text-align: justify\"><b><i>Expert opinion:<\/i><\/b> The extensive clinical variability and genetic heterogeneity of GSDs renders this broad group of rare diseases a bench to bedside challenge. However, the evolving hypothesis that clinically different diseases might share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.<\/div>\n<div class=\"paragraph\" style=\"text-align: justify\"><\/div>\n<p>Full text available from Journal website<span style=\"color: #ff6600\"><strong> <a style=\"color: #ff6600\" href=\"http:\/\/www.tandfonline.com\/toc\/ieod20\/3\/10\">here<\/a><\/strong><\/span><\/p>\n<p>Or download a .pdf file here: <span style=\"color: #ff6600\"><strong><a style=\"color: #ff6600\" href=\"https:\/\/blogs.ncl.ac.uk\/katarzynapirog\/files\/2016\/01\/review.pdf\" rel=\"\">review<\/a><\/strong><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abstract Introduction: Genetic skeletal diseases (GSDs) are a diverse and complex group of rare genetic conditions that affect the development and homeostasis of the skeleton. Although individually rare, as a group of related diseases, GSDs have an overall prevalence of at least 1 per 4,000 children. There are currently very few specific therapeutic interventions to &hellip; <a href=\"https:\/\/blogs.ncl.ac.uk\/piroglab\/2015\/09\/25\/new-therapeutic-targets-in-rare-genetic-skeletal-diseases\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">New therapeutic targets in rare genetic skeletal diseases &#8211; an Expert Opinion review<\/span> <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":4483,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-92","post","type-post","status-publish","format-standard","hentry","category-publications"],"_links":{"self":[{"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/posts\/92","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/users\/4483"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/comments?post=92"}],"version-history":[{"count":4,"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/posts\/92\/revisions"}],"predecessor-version":[{"id":151,"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/posts\/92\/revisions\/151"}],"wp:attachment":[{"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/media?parent=92"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/categories?post=92"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.ncl.ac.uk\/piroglab\/wp-json\/wp\/v2\/tags?post=92"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}